HK1253532A1 - 用於治療變應性、炎性和感染性疾病的嘌呤衍生物 - Google Patents
用於治療變應性、炎性和感染性疾病的嘌呤衍生物Info
- Publication number
- HK1253532A1 HK1253532A1 HK18112732.8A HK18112732A HK1253532A1 HK 1253532 A1 HK1253532 A1 HK 1253532A1 HK 18112732 A HK18112732 A HK 18112732A HK 1253532 A1 HK1253532 A1 HK 1253532A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- allergic
- inflammatory
- treatment
- infectious diseases
- purine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8777708P | 2008-08-11 | 2008-08-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1253532A1 true HK1253532A1 (zh) | 2019-06-21 |
Family
ID=41187189
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11112171.3A HK1157770A1 (zh) | 2008-08-11 | 2011-11-10 | 用於治療變應性、炎性和感染性疾病的嘌呤衍生物 |
HK16111100.6A HK1222857A1 (zh) | 2008-08-11 | 2016-09-21 | 用於治療變應性、炎性和感染性疾病的嘌呤衍生物 |
HK18112732.8A HK1253532A1 (zh) | 2008-08-11 | 2018-10-05 | 用於治療變應性、炎性和感染性疾病的嘌呤衍生物 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK11112171.3A HK1157770A1 (zh) | 2008-08-11 | 2011-11-10 | 用於治療變應性、炎性和感染性疾病的嘌呤衍生物 |
HK16111100.6A HK1222857A1 (zh) | 2008-08-11 | 2016-09-21 | 用於治療變應性、炎性和感染性疾病的嘌呤衍生物 |
Country Status (38)
Country | Link |
---|---|
US (7) | US8067426B2 (zh) |
EP (3) | EP3336089A1 (zh) |
JP (1) | JP5529867B2 (zh) |
KR (1) | KR101669939B1 (zh) |
CN (2) | CN104098568B (zh) |
AU (1) | AU2009281197B2 (zh) |
BR (1) | BRPI0917138A2 (zh) |
CA (1) | CA2733749C (zh) |
CL (1) | CL2011000301A1 (zh) |
CO (1) | CO6351791A2 (zh) |
CR (1) | CR20110116A (zh) |
CY (1) | CY1119992T1 (zh) |
DK (2) | DK2324026T3 (zh) |
DO (1) | DOP2011000048A (zh) |
EA (1) | EA020631B1 (zh) |
ES (2) | ES2661671T3 (zh) |
HK (3) | HK1157770A1 (zh) |
HR (2) | HRP20150938T1 (zh) |
HU (2) | HUE036570T2 (zh) |
IL (1) | IL210757A (zh) |
LT (1) | LT3000813T (zh) |
MA (1) | MA32624B1 (zh) |
ME (1) | ME02274B (zh) |
MX (2) | MX336345B (zh) |
MY (1) | MY162538A (zh) |
NO (1) | NO3000813T3 (zh) |
NZ (2) | NZ590782A (zh) |
PE (1) | PE20110674A1 (zh) |
PL (2) | PL3000813T3 (zh) |
PT (2) | PT3000813T (zh) |
RS (2) | RS56984B1 (zh) |
SG (1) | SG192547A1 (zh) |
SI (2) | SI2324026T1 (zh) |
SM (1) | SMT201500224B (zh) |
TR (1) | TR201802648T4 (zh) |
UA (1) | UA103195C2 (zh) |
WO (1) | WO2010018133A1 (zh) |
ZA (1) | ZA201100845B (zh) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1728793B1 (en) * | 2004-03-26 | 2016-02-03 | Sumitomo Dainippon Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
MX2007012393A (es) * | 2005-04-05 | 2008-02-22 | Pharmacopeia Inc | Derivados de purina e imidazopiridina para la inmunosupresion. |
JPWO2007034817A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
JP2009542645A (ja) * | 2006-07-05 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体 |
TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
ATE490249T1 (de) * | 2007-02-19 | 2010-12-15 | Glaxosmithkline Llc | Purinderivate als immunmodulatoren |
WO2008114006A1 (en) * | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
WO2008114008A1 (en) * | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
JPWO2008114819A1 (ja) * | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
MY150519A (en) * | 2007-05-08 | 2014-01-30 | Astrazeneca Ab | Imidazoquinolines with immuno-modulating properties |
US7968544B2 (en) * | 2007-06-29 | 2011-06-28 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
UY31531A1 (es) | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
WO2009091032A1 (ja) | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co., Ltd. | アデニン化合物の製造方法 |
WO2009091031A1 (ja) * | 2008-01-17 | 2009-07-23 | Dainippon Sumitomo Pharma Co., Ltd. | アデニン化合物の製造方法 |
UA103195C2 (uk) * | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
US8575181B2 (en) | 2008-08-11 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
ES2640535T3 (es) | 2008-08-11 | 2017-11-03 | Glaxosmithkline Llc | Derivados novedosos de adenina |
WO2010077613A1 (en) | 2008-12-09 | 2010-07-08 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
EA201791383A1 (ru) | 2009-05-27 | 2018-06-29 | Селекта Байосайенсиз, Инк. | Наноносители, имеющие компоненты с различными скоростями высвобождения |
NZ598933A (en) | 2009-10-22 | 2013-04-26 | Gilead Sciences Inc | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections |
WO2011068233A1 (en) * | 2009-12-03 | 2011-06-09 | Dainippon Sumitomo Pharma Co., Ltd. | Imidazoquinolines which act via toll - like receptors (tlr) |
WO2011079016A1 (en) * | 2009-12-22 | 2011-06-30 | Gilead Sciences, Inc. | Methods of treating hbv and hcv infection |
US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
CA2786973C (en) | 2010-02-10 | 2018-04-10 | Robert Hermann Gibbon | 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
DK2575876T3 (en) | 2010-05-26 | 2018-03-12 | Selecta Biosciences Inc | MULTIVALENT VACCINES WITH SYNTHETIC NANO CARRIERS |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS |
CN103370317B (zh) | 2010-12-16 | 2015-10-07 | 阿斯利康(瑞典)有限公司 | 可用于治疗的咪唑并[4,5-c]喹啉-1-基衍生物 |
WO2012080730A1 (en) | 2010-12-17 | 2012-06-21 | Astrazeneca Ab | Purine derivatives |
KR20200057789A (ko) | 2011-04-29 | 2020-05-26 | 셀렉타 바이오사이언시즈, 인크. | 합성 나노운반체로부터의 면역억제제의 조절 방출 |
RS57995B1 (sr) * | 2011-07-22 | 2019-01-31 | Glaxosmithkline Llc | Kompozicija |
CN109125722A (zh) | 2011-07-29 | 2019-01-04 | 西莱克塔生物科技公司 | 产生体液和细胞毒性t淋巴细胞(ctl)免疫应答的合成纳米载体 |
GB201120000D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
GB201119999D0 (en) | 2011-11-20 | 2012-01-04 | Glaxosmithkline Biolog Sa | Vaccine |
EP2674170B1 (en) | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
PE20150730A1 (es) | 2012-08-24 | 2015-06-02 | Glaxosmithkline Llc | Compuestos de pirazolopirimidina |
EP2732825B1 (en) | 2012-11-19 | 2015-07-01 | Invivogen | Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist |
AU2013348217B2 (en) | 2012-11-20 | 2016-10-06 | Glaxosmithkline Llc | Novel compounds |
EP2922549B1 (en) | 2012-11-20 | 2017-06-21 | Glaxosmithkline LLC | Novel compounds |
RU2640200C2 (ru) * | 2012-11-20 | 2017-12-27 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
EP2769738B1 (en) | 2013-02-22 | 2016-07-20 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
RU2676684C2 (ru) * | 2014-02-20 | 2019-01-10 | ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА |
EP3556353A3 (en) | 2014-02-25 | 2020-03-18 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
CA2953507A1 (en) | 2014-06-25 | 2015-12-30 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
MA40238A (fr) | 2014-07-11 | 2017-05-17 | Gilead Sciences Inc | Modulateurs de récepteurs de type toll pour le traitement du vih |
US9738646B2 (en) | 2014-09-16 | 2017-08-22 | Gilead Sciences, Inc. | Solid forms of a toll-like receptor modulator |
BE1023340B1 (fr) * | 2014-11-13 | 2017-02-08 | Glaxosmithkline Biologicals S.A. | Composes |
WO2017205383A1 (en) * | 2016-05-23 | 2017-11-30 | University Of Iowa Research Foundation | Method of treating cystic fibrosis airway disease |
EP3464312A4 (en) * | 2016-06-02 | 2019-11-27 | Celgene Corporation | ANTI-TRYPANOSOMA AND ANTI-LEISHMANIA AGENTS FOR ANIMALS AND HUMANS |
US11253476B2 (en) | 2017-03-29 | 2022-02-22 | Sumitomo Dainippon Pharma Co., Ltd. | Vaccine adjuvant formulation |
CN108948016B (zh) * | 2017-05-19 | 2021-02-26 | 江苏恒瑞医药股份有限公司 | 嘌呤酮类衍生物、其制备方法及其在医药上的应用 |
KR20200088398A (ko) | 2017-11-14 | 2020-07-22 | 칠드런'즈 메디컬 센터 코포레이션 | 인간 면역 반응을 조정하기 위한 이미다조피리미딘의 용도 |
US11673891B2 (en) | 2017-11-14 | 2023-06-13 | Dana-Farber Cancer Institute, Inc. | Imidazopyrimidine compounds and uses thereof |
WO2019097696A1 (ja) | 2017-11-17 | 2019-05-23 | 株式会社Nttドコモ | ユーザ端末及び無線通信方法 |
SG11202005535UA (en) | 2017-12-21 | 2020-07-29 | Sumitomo Dainippon Pharma Co Ltd | Combination drug including tlr7 agonist |
CA3107409A1 (en) | 2018-07-23 | 2020-01-30 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Composition containing influenza vaccine |
US11486970B1 (en) | 2019-02-11 | 2022-11-01 | Innovusion, Inc. | Multiple beam generation from a single source beam for use with a LiDAR system |
WO2020237164A1 (en) | 2019-05-23 | 2020-11-26 | The University Of Montana | Vaccine adjuvants based on tlr receptor ligands |
WO2020263660A1 (en) * | 2019-06-24 | 2020-12-30 | Merck Sharp & Dohme Corp. | Process for the preparation of 2-fluoroadenine |
CN110772523B (zh) * | 2019-11-07 | 2020-06-26 | 黑龙江中医药大学 | 一种用于防治肾病的药物组合物 |
WO2024028794A1 (en) | 2022-08-02 | 2024-02-08 | Temple Therapeutics BV | Methods for treating endometrial and ovarian hyperproliferative disorders |
Family Cites Families (117)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
TW530047B (en) | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US7067664B1 (en) | 1995-06-06 | 2006-06-27 | Pfizer Inc. | Corticotropin releasing factor antagonists |
WO1997049706A1 (en) | 1996-06-25 | 1997-12-31 | Novartis Ag | SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF |
US6126919A (en) | 1997-02-07 | 2000-10-03 | 3M Innovative Properties Company | Biocompatible compounds for pharmaceutical drug delivery systems |
US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
EP1065213A3 (en) | 1999-07-02 | 2003-11-05 | Japan Tobacco Inc. | HCV polymerase suitable for crystal structure analysis and method for using the enzyme |
CZ20013424A3 (cs) | 1999-12-27 | 2002-02-13 | Japan Tobacco Inc. | Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva |
WO2001049688A1 (en) | 2000-01-07 | 2001-07-12 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
CA2407594A1 (en) | 2000-04-28 | 2001-11-08 | Acadia Pharmaceuticals, Inc. | Muscarinic agonists |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
KR100828453B1 (ko) | 2001-01-22 | 2008-05-13 | 머크 앤드 캄파니 인코포레이티드 | Rna 의존성 rna 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체 |
PL364469A1 (en) | 2001-03-19 | 2004-12-13 | Ono Pharmaceutical Co, Ltd. | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
GB0114286D0 (en) * | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
US7126880B2 (en) | 2001-06-29 | 2006-10-24 | Trigger Co. Ltd. | Radio wristwatch |
US6841566B2 (en) | 2001-07-20 | 2005-01-11 | Boehringer Ingelheim, Ltd. | Viral polymerase inhibitors |
TW200301251A (en) | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
DK1348707T3 (da) | 2002-03-28 | 2010-12-13 | Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro | Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse |
US20030215917A1 (en) | 2002-04-04 | 2003-11-20 | Mingjun Huang | Assay for evaluation of activity of compounds against HCV using a novel detection system in the HCV replicon |
US20040063658A1 (en) | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
US6713241B2 (en) | 2002-08-09 | 2004-03-30 | Eastman Kodak Company | Thermally developable emulsions and imaging materials containing binder mixture |
BRPI0313664B8 (pt) | 2002-08-21 | 2021-05-25 | Albert Einstein College Medicine Yeshiva Univ | compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos |
JP4768263B2 (ja) | 2002-09-27 | 2011-09-07 | 大日本住友製薬株式会社 | 新規アデニン化合物及びその用途 |
AU2003276172A1 (en) | 2002-10-24 | 2004-05-13 | Glaxo Group Limited | 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
JP2006514950A (ja) | 2002-12-13 | 2006-05-18 | スミスクライン ビーチャム コーポレーション | Ccr5拮抗薬としてのシクロプロピル化合物 |
ATE402176T1 (de) | 2002-12-13 | 2008-08-15 | Smithkline Beecham Corp | Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten |
EP1581530A1 (en) | 2002-12-13 | 2005-10-05 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
JP2006514646A (ja) | 2002-12-13 | 2006-05-11 | スミスクライン ビーチャム コーポレーション | Ccr5アンタゴニストとしてのシクロヘキシル化合物類 |
ES2312856T3 (es) | 2002-12-13 | 2009-03-01 | Smithkline Beecham Corporation | Compuestos heterociclicos como antagonistas de ccr5. |
KR20050087832A (ko) | 2002-12-13 | 2005-08-31 | 스미스클라인 비참 코포레이션 | Ccr5 길항제로서 피페리딘 유도체 |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
EP1646614A4 (en) | 2003-07-01 | 2008-09-10 | Merck & Co Inc | OPHTHALMIC COMPOSITIONS FOR THE TREATMENT OF OCCULAR HYPERTONIA |
WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
US20070161582A1 (en) | 2003-08-08 | 2007-07-12 | Dusan Mijikovic | Pharmaceutical compositions and methods for metabolic modulation |
CA2537450C (en) | 2003-09-05 | 2012-04-17 | Anadys Pharmaceuticals, Inc. | Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus |
SG149829A1 (en) | 2003-10-03 | 2009-02-27 | 3M Innovative Properties Co | Pyrazolopyridines and analogs thereof |
BRPI0416128B8 (pt) | 2003-11-03 | 2021-06-22 | Glaxo Group Ltd | dispositivo de dispensação de fluido |
PL1550656T3 (pl) | 2003-12-01 | 2009-09-30 | Oreal | Skondensowane pochodne 4-5-diamino-N,N-dihydro-pirazol-3-onu do zastosowania w kompozycji do farbowania włókien keratynowych |
PT1718608E (pt) | 2004-02-20 | 2013-08-01 | Boehringer Ingelheim Int | Inibidores da polimerase viral |
EP1728793B1 (en) * | 2004-03-26 | 2016-02-03 | Sumitomo Dainippon Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
US20070225303A1 (en) * | 2004-03-26 | 2007-09-27 | Haruhisa Ogita | 8-Oxoadenine Compound |
US7857162B2 (en) | 2004-03-31 | 2010-12-28 | Yuyama Mfg. Co., Ltd. | Tablet feeder |
EP1740591B1 (en) | 2004-04-02 | 2009-06-17 | OSI Pharmaceuticals, Inc. | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
CA2564175A1 (en) | 2004-04-28 | 2005-11-10 | Arrow Therapeutics Limited | Chemical compounds |
US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
AP2313A (en) | 2004-08-18 | 2011-10-31 | Pfizer | Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same. |
US20060045885A1 (en) | 2004-08-27 | 2006-03-02 | Kedl Ross M | Method of eliciting an immune response against HIV |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
WO2006117670A1 (en) * | 2005-05-04 | 2006-11-09 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
JP2008540537A (ja) | 2005-05-09 | 2008-11-20 | アキリオン ファーマシューティカルズ,インコーポレーテッド | チアゾール化合物および使用方法 |
NZ540160A (en) | 2005-05-20 | 2008-03-28 | Einstein Coll Med | Inhibitors of nucleoside phosphorylases |
US7932257B2 (en) | 2005-07-22 | 2011-04-26 | Sunesis Pharmaceuticals, Inc. | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors |
WO2007024707A2 (en) * | 2005-08-22 | 2007-03-01 | The Regents Of The University Of California | Tlr agonists |
US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
ATE517883T1 (de) | 2005-08-25 | 2011-08-15 | Schering Corp | Imidazolderivate als funktionelle selektive agonisten des alpha2c-adrenorezeptors |
CA2620933A1 (en) | 2005-09-02 | 2007-03-08 | Pfizer Inc. | Hydroxy substituted 1h-imidazopyridines and methods |
TW200801003A (en) * | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
EP1939198A4 (en) * | 2005-09-22 | 2012-02-15 | Dainippon Sumitomo Pharma Co | NEW ADENINE CONNECTION |
WO2007034882A1 (ja) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | 新規アデニン化合物 |
JPWO2007034817A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
JPWO2007034917A1 (ja) * | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規なアデニン化合物 |
TW200745114A (en) * | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
US20090099216A1 (en) * | 2005-09-22 | 2009-04-16 | Astrazeneca Aktiebolag A Corporation Of Sweden | Novel adenine compound |
CN1947717B (zh) | 2005-10-14 | 2012-09-26 | 卓敏 | 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 |
EP1987030B1 (en) | 2006-02-17 | 2011-11-09 | Pfizer Limited | 3 -deazapurine derivatives as tlr7 modulators |
CA2914168C (en) | 2006-03-28 | 2018-05-08 | Atir Holding S.A. | Pyrido[1,2-a]pyrimidin-4-one derivatives and their use in the treatment of sexual disorders |
GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
US8846697B2 (en) * | 2006-05-31 | 2014-09-30 | The Regents Of The University Of California | Purine analogs |
US20070282962A1 (en) | 2006-06-01 | 2007-12-06 | Microsoft Corporation | Auto-Subscribing to Syndication Feeds Using Contact Lists |
JP2009542645A (ja) | 2006-07-05 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | Tlr7のモジュレーターとして作用する8−オキソアデニン誘導体 |
WO2008005555A1 (en) * | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
TW200831105A (en) * | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
ATE490249T1 (de) | 2007-02-19 | 2010-12-15 | Glaxosmithkline Llc | Purinderivate als immunmodulatoren |
WO2008114006A1 (en) * | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7) modulators |
WO2008114008A1 (en) * | 2007-03-19 | 2008-09-25 | Astrazeneca Ab | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
JPWO2008114819A1 (ja) * | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
AR065784A1 (es) * | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas. |
US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
US7968544B2 (en) * | 2007-06-29 | 2011-06-28 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
EA201000201A1 (ru) | 2007-08-10 | 2010-12-30 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Азотсодержащие бициклические химические вещества для лечения вирусных инфекций |
UY31531A1 (es) | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
ES2640535T3 (es) | 2008-08-11 | 2017-11-03 | Glaxosmithkline Llc | Derivados novedosos de adenina |
US8575181B2 (en) | 2008-08-11 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
EP2324025A1 (en) | 2008-08-11 | 2011-05-25 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
WO2010083725A1 (zh) | 2009-01-20 | 2010-07-29 | 山东轩竹医药科技有限公司 | 含有取代的含氮稠杂环的头孢菌素衍生物 |
TR201909600T4 (tr) | 2009-08-07 | 2019-07-22 | Glaxosmithkline Biologicals Sa | Lipide edilmiş oksoadenin türevleri. |
US8575340B2 (en) | 2010-02-10 | 2013-11-05 | Glaxosmithkline Llc | Purine derivatives and their pharmaceutical uses |
CA2786973C (en) | 2010-02-10 | 2018-04-10 | Robert Hermann Gibbon | 6-amino-2-{[(1s)-1-methylbutyl] oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8h-purin-8-one maleate |
WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
US20120171229A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
ES2734878T3 (es) | 2011-02-01 | 2019-12-12 | Univ Illinois | Derivados de N-hidroxibenzamida como inhibidores de HDAC y métodos terapéuticos que utilizan los mismos |
US9139590B2 (en) | 2011-02-04 | 2015-09-22 | Duquesne University Of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
RS57995B1 (sr) | 2011-07-22 | 2019-01-31 | Glaxosmithkline Llc | Kompozicija |
PE20150730A1 (es) | 2012-08-24 | 2015-06-02 | Glaxosmithkline Llc | Compuestos de pirazolopirimidina |
EP2922549B1 (en) | 2012-11-20 | 2017-06-21 | Glaxosmithkline LLC | Novel compounds |
RU2640200C2 (ru) | 2012-11-20 | 2017-12-27 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Новые соединения |
AU2013348217B2 (en) | 2012-11-20 | 2016-10-06 | Glaxosmithkline Llc | Novel compounds |
RU2676684C2 (ru) | 2014-02-20 | 2019-01-10 | ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА |
-
2009
- 2009-07-08 UA UAA201100703A patent/UA103195C2/uk unknown
- 2009-08-07 PT PT151701430T patent/PT3000813T/pt unknown
- 2009-08-07 DK DK09781606.0T patent/DK2324026T3/en active
- 2009-08-07 JP JP2011522486A patent/JP5529867B2/ja not_active Expired - Fee Related
- 2009-08-07 EP EP17205469.4A patent/EP3336089A1/en not_active Withdrawn
- 2009-08-07 MY MYPI2011000594A patent/MY162538A/en unknown
- 2009-08-07 CA CA2733749A patent/CA2733749C/en not_active Expired - Fee Related
- 2009-08-07 ES ES15170143.0T patent/ES2661671T3/es active Active
- 2009-08-07 DK DK15170143.0T patent/DK3000813T3/da active
- 2009-08-07 SG SG2013055884A patent/SG192547A1/en unknown
- 2009-08-07 US US12/537,392 patent/US8067426B2/en active Active
- 2009-08-07 AU AU2009281197A patent/AU2009281197B2/en not_active Ceased
- 2009-08-07 EA EA201100113A patent/EA020631B1/ru not_active IP Right Cessation
- 2009-08-07 KR KR1020117005860A patent/KR101669939B1/ko active IP Right Grant
- 2009-08-07 EP EP09781606.0A patent/EP2324026B1/en active Active
- 2009-08-07 NZ NZ590782A patent/NZ590782A/xx not_active IP Right Cessation
- 2009-08-07 RS RS20180242A patent/RS56984B1/sr unknown
- 2009-08-07 SI SI200931267T patent/SI2324026T1/sl unknown
- 2009-08-07 LT LTEP15170143.0T patent/LT3000813T/lt unknown
- 2009-08-07 SI SI200931799T patent/SI3000813T1/en unknown
- 2009-08-07 WO PCT/EP2009/060265 patent/WO2010018133A1/en active Application Filing
- 2009-08-07 CN CN201410287455.6A patent/CN104098568B/zh not_active Expired - Fee Related
- 2009-08-07 NO NO15170143A patent/NO3000813T3/no unknown
- 2009-08-07 HU HUE15170143A patent/HUE036570T2/hu unknown
- 2009-08-07 CN CN200980141103.7A patent/CN102177159B/zh not_active Expired - Fee Related
- 2009-08-07 EP EP15170143.0A patent/EP3000813B1/en active Active
- 2009-08-07 PL PL15170143T patent/PL3000813T3/pl unknown
- 2009-08-07 HU HUE09781606A patent/HUE027637T2/en unknown
- 2009-08-07 PE PE2011000155A patent/PE20110674A1/es active IP Right Grant
- 2009-08-07 MX MX2012012018A patent/MX336345B/es unknown
- 2009-08-07 BR BRPI0917138A patent/BRPI0917138A2/pt not_active Application Discontinuation
- 2009-08-07 ES ES09781606.0T patent/ES2549154T3/es active Active
- 2009-08-07 TR TR2018/02648T patent/TR201802648T4/tr unknown
- 2009-08-07 NZ NZ602812A patent/NZ602812A/en not_active IP Right Cessation
- 2009-08-07 MX MX2011001666A patent/MX2011001666A/es active IP Right Grant
- 2009-08-07 RS RS20150606A patent/RS54266B1/en unknown
- 2009-08-07 ME MEP-2015-138A patent/ME02274B/me unknown
- 2009-08-07 US US13/058,470 patent/US8765772B2/en active Active
- 2009-08-07 PL PL09781606T patent/PL2324026T3/pl unknown
- 2009-08-07 PT PT97816060T patent/PT2324026E/pt unknown
-
2011
- 2011-01-19 CO CO11005402A patent/CO6351791A2/es not_active Application Discontinuation
- 2011-01-20 IL IL210757A patent/IL210757A/en active IP Right Grant
- 2011-02-01 ZA ZA2011/00845A patent/ZA201100845B/en unknown
- 2011-02-08 DO DO2011000048A patent/DOP2011000048A/es unknown
- 2011-02-11 CL CL2011000301A patent/CL2011000301A1/es unknown
- 2011-03-03 CR CR20110116A patent/CR20110116A/es unknown
- 2011-03-08 MA MA33686A patent/MA32624B1/fr unknown
- 2011-10-13 US US13/272,956 patent/US9346806B2/en not_active Expired - Fee Related
- 2011-11-10 HK HK11112171.3A patent/HK1157770A1/zh not_active IP Right Cessation
-
2014
- 2014-05-16 US US14/280,115 patent/US9233962B2/en not_active Expired - Fee Related
-
2015
- 2015-09-07 HR HRP20150938TT patent/HRP20150938T1/hr unknown
- 2015-09-22 SM SM201500224T patent/SMT201500224B/xx unknown
-
2016
- 2016-04-21 US US15/134,623 patent/US9877968B2/en active Active
- 2016-09-21 HK HK16111100.6A patent/HK1222857A1/zh not_active IP Right Cessation
-
2017
- 2017-12-19 US US15/846,475 patent/US10117873B2/en not_active Expired - Fee Related
-
2018
- 2018-02-02 HR HRP20180202TT patent/HRP20180202T1/hr unknown
- 2018-02-28 CY CY20181100258T patent/CY1119992T1/el unknown
- 2018-10-01 US US16/148,125 patent/US20190038631A1/en not_active Abandoned
- 2018-10-05 HK HK18112732.8A patent/HK1253532A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1253532A1 (zh) | 用於治療變應性、炎性和感染性疾病的嘌呤衍生物 | |
ZA201101105B (en) | Purine derivatives for use in the treatment of allergic,inflammatory and infectious diseases | |
HK1153926A1 (zh) | 用於治療 -相關疾病的嘌呤衍生物 | |
HRP20191953T8 (hr) | DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CX3CR1 i P40 | |
IL232256A0 (en) | Purine derivatives and their use in the treatment of diseases | |
ZA201000075B (en) | Purin derivatives for use in the treatment of fab-related diseases | |
PL2254870T3 (pl) | Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CX3CR1 | |
IL216967B (en) | The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases | |
EP2262777B8 (en) | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1 and cx3cr1 | |
SI2148667T1 (sl) | Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni | |
ZA201108106B (en) | Use of phthalimide derivatives in the treatment of diseases | |
HK1158954A1 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases | |
HRP20151393T8 (hr) | UPORABA BENZIDAMINA U LIJEČENJU BOLESTI KOJE SU p40-OVISNE | |
HK1144247A1 (en) | Use of osteoblasts in the treatment of inflammatory rheumatic diseases | |
TH0901005786A (th) | อนุพันธ์พิวรีนเพื่อใช้ในการรักษาโรคภูมิแพ้, อาการอักเสบ และโรคติดเชื้อ | |
IL202502A0 (en) | Agents for the treatment of inflammatory diseases and methods of using same |